New initiatives for LENVIMA®

Grupo Biotoscana announces new initiatives for LENVIMA®

Montevideo, Uruguay, March 12, 2018. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces that, last week, our partner, Eisai Co., Ltd., announced a separate arrangement for our key partnered drug LENVIMA® (lenvatinib).

Under a new agreement between Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A (known as MSD outside the United States and Canada), Eisai and MSD co-develop and co-commercialize LENVIMA® (lenvatinib mesylate), as monotherapy and in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

GBT reinforces its commitment to commercialize LENVIMA® (lenvatinib) and clarifies that the arrangement between Eisai and MSD does not change, GBT’s rights to LENVIMA® (lenvatinib), which were the subject of a previous agreement between GBT and Eisai, and GBT will continue to book 100% of the sales of LENVIMA® (lenvatinib) in GBT‘s territory.

See the full article.

About GBT-Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit

LENVIMA® (lenvatinib) is a novel multiple receptor tyrosine kinase inhibitor (orally administered molecular-targeted agent) discovered and developed by Eisai. Launched as a treatment for refractory thyroid cancer in the United States, Japan and Europe in 2015 and has been granted orphan drug status (a drug for rare diseases) for the treatment of thyroid cancer by the regulatory authorities in each of these regions. LENVIMA is also indicated to treat adults with a form of advanced kidney cancer.

Forward-Looking Statements (GBT)
This release includes forward-looking statements concerning a transaction between GBT-Grupo Biotoscana and EISAI, including expectations regarding the applicability of predictions to the commercialization of certain products. GBT-Grupo Biotoscana disclaims any obligation to update any forward-looking statement, except as required by applicable law.